(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 19.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.15%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.98%.
Mirum Pharmaceuticals's revenue in 2026 is $618,067,000.On average, 15 Wall Street analysts forecast MIRM's revenue for 2026 to be $46,234,975,146, with the lowest MIRM revenue forecast at $43,605,870,247, and the highest MIRM revenue forecast at $48,305,013,778. On average, 14 Wall Street analysts forecast MIRM's revenue for 2027 to be $54,279,425,776, with the lowest MIRM revenue forecast at $47,740,103,612, and the highest MIRM revenue forecast at $60,168,127,266.
In 2028, MIRM is forecast to generate $70,581,304,661 in revenue, with the lowest revenue forecast at $61,446,642,343 and the highest revenue forecast at $81,035,389,344.